Alzheimer’s drug donanemab finds late-stage trial success, safety concerns
By
Alicia Lasek
May 04, 2023
The experimental drug donanemab appears to halt the progression of Alzheimer’s disease and slow certain measures of clinical decline, new trial data show.
Patient advocates decry CMS decision on Alzheimer’s drug coverage
By
Alicia Lasek
Feb 24, 2023
The Alzheimer’s Association and others have strongly criticized a decision by CMS to stand by its highly restrictive coverage for new dementia drugs.